-DOCSTART- -X- O
Active -X- _ O
immunization -X- _ O
is -X- _ O
an -X- _ O
effective -X- _ O
means -X- _ O
of -X- _ O
blocking -X- _ O
the -X- _ O
pharmacodynamic -X- _ O
effects -X- _ O
of -X- _ O
drugs -X- _ O
and -X- _ O
holds -X- _ O
promise -X- _ O
as -X- _ O
a -X- _ O
treatment -X- _ O
for -X- _ O
heroin -X- _ O
addiction. -X- _ O
Previously -X- _ O
, -X- _ O
we -X- _ O
demonstrated -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
our -X- _ O
first-generation -X- _ O
vaccine -X- _ O
in -X- _ O
blocking -X- _ O
heroin -X- _ O
self-administration -X- _ O
in -X- _ O
rats -X- _ O
, -X- _ O
however -X- _ O
, -X- _ O
many -X- _ O
vaccine -X- _ O
components -X- _ O
can -X- _ O
be -X- _ O
modified -X- _ O
to -X- _ O
further -X- _ O
improve -X- _ O
performance. -X- _ O
Herein -X- _ O
we -X- _ O
examine -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
varying -X- _ B-Intervention
heroin -X- _ I-Intervention
vaccine -X- _ I-Intervention
injection -X- _ I-Intervention
route -X- _ I-Intervention
and -X- _ I-Intervention
adjuvant -X- _ I-Intervention
formulation. -X- _ I-Intervention
Mice -X- _ B-Patient
immunized -X- _ B-Outcome
via -X- _ I-Outcome
subcutaneous -X- _ I-Outcome
( -X- _ I-Outcome
sc -X- _ I-Outcome
) -X- _ I-Outcome
injection -X- _ I-Outcome
exhibited -X- _ I-Outcome
inferior -X- _ I-Outcome
anti-heroin -X- _ I-Outcome
titers -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
intraperitoneal -X- _ I-Outcome
( -X- _ I-Outcome
ip -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
sc -X- _ I-Outcome
/ -X- _ I-Outcome
ip -X- _ I-Outcome
coadministration -X- _ I-Outcome
injection -X- _ I-Outcome
routes. -X- _ I-Outcome
Addition -X- _ I-Outcome
of -X- _ I-Outcome
TLR9 -X- _ I-Outcome
agonist -X- _ I-Outcome
cytosine- -X- _ I-Outcome
guanine -X- _ I-Outcome
oligodeoxynucleotide -X- _ I-Outcome
1826 -X- _ I-Outcome
( -X- _ I-Outcome
CpG -X- _ I-Outcome
ODN -X- _ I-Outcome
1826 -X- _ I-Outcome
) -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
original -X- _ I-Outcome
alum -X- _ I-Outcome
adjuvant -X- _ I-Outcome
elicited -X- _ I-Outcome
superior -X- _ I-Outcome
antibody -X- _ I-Outcome
titers -X- _ I-Outcome
and -X- _ I-Outcome
opioid -X- _ I-Outcome
affinities -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
alum -X- _ I-Outcome
alone. -X- _ I-Outcome
To -X- _ O
thoroughly -X- _ O
assess -X- _ O
vaccine -X- _ O
efficacy -X- _ O
, -X- _ O
full -X- _ O
dose–response -X- _ O
curves -X- _ O
were -X- _ O
generated -X- _ O
for -X- _ O
heroin-induced -X- _ O
analgesia -X- _ O
in -X- _ O
both -X- _ O
hot -X- _ O
plate -X- _ O
and -X- _ O
tail -X- _ O
immersion -X- _ O
tests. -X- _ O
Mice -X- _ B-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
CpG -X- _ I-Outcome
ODN -X- _ I-Outcome
1826 -X- _ I-Outcome
exhibited -X- _ I-Outcome
greatly -X- _ I-Outcome
shifted -X- _ I-Outcome
dose–response -X- _ I-Outcome
curves -X- _ I-Outcome
( -X- _ I-Outcome
10–13-fold -X- _ I-Outcome
vs -X- _ I-Outcome
unvaccinated -X- _ I-Outcome
controls -X- _ I-Outcome
) -X- _ I-Outcome
while -X- _ I-Outcome
non-CpG -X- _ I-Outcome
ODN -X- _ I-Outcome
vaccine -X- _ I-Outcome
groups -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
exhibit -X- _ I-Outcome
the -X- _ I-Outcome
same -X- _ I-Outcome
robust -X- _ I-Outcome
effect -X- _ I-Outcome
( -X- _ I-Outcome
2–7-fold -X- _ I-Outcome
shift -X- _ I-Outcome
for -X- _ I-Outcome
ip -X- _ I-Outcome
and -X- _ I-Outcome
combo -X- _ I-Outcome
, -X- _ I-Outcome
2–3-fold -X- _ I-Outcome
shift -X- _ I-Outcome
for -X- _ I-Outcome
sc -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Our -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
CpG -X- _ B-Outcome
ODN -X- _ I-Outcome
1826 -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
highly -X- _ I-Outcome
potent -X- _ I-Outcome
adjuvant -X- _ I-Outcome
, -X- _ O
and -X- _ O
injection -X- _ O
routes -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
for -X- _ O
development -X- _ O
of -X- _ O
small -X- _ O
molecule–protein -X- _ O
conjugate -X- _ O
vaccines. -X- _ O
Lastly -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
has -X- _ O
established -X- _ O
a -X- _ O
new -X- _ O
standard -X- _ O
for -X- _ O
assessing -X- _ O
drugs -X- _ O
of -X- _ O
abuse -X- _ O
vaccines -X- _ O
, -X- _ O
wherein -X- _ O
a -X- _ O
full -X- _ O
dose–response -X- _ O
curve -X- _ O
should -X- _ O
be -X- _ O
performed -X- _ O
in -X- _ O
an -X- _ O
appropriate -X- _ O
behavioral -X- _ O
task -X- _ O
. -X- _ O

